(Boehringer Ingelheim) Protection from rhinopneumonitis respiratory disease caused by EHV-4 and EHV-1. Maximum influenza protection includes new strains Ohio/2003, Kentucky 2/95 and Newmarket 2/93. For initial vaccination, give 2 ml IM, followed by a 2nd dose IM in 3-4 weeks. Administer a third dose 3-4 weeks later either IM or intranasally. Revaccinate annually prior to anticipated exposure.